Media Articles Related to Tenoretic (Atenolol / Chlorthalidone)
AHA, Hypertension Society Mull a Merger
Source: MedPage Today Cardiology [2016.09.20]
(MedPage Today) -- Heart association would absorb ASH members, activities
Innovative sound therapy treats hypertension and migraine
Source: Headache / Migraine News From Medical News Today [2016.09.17]
A groundbreaking device that aligns the left and right brain using sound alone may reduce the symptoms of migraine, hypertension, and insomnia.
Genetically-modified probiotic may one day treat pulmonary hypertension
Source: Cardiovascular / Cardiology News From Medical News Today [2016.09.15]
An oral, genetically-modified strain of the probiotic Lactobacillus was used to treat rats with high blood pressure in the lungs, which resulted in reduced blood pressure, improved heart...
Hypertension: Releasing the pressure at its source
Source: Hypertension News From Medical News Today [2016.09.07]
Researchers eyeing first new anti-hypertensive drug treatment strategy in more than 15 years.
Source: MedicineNet Alcohol Abuse and Alcoholism Specialty [2016.09.06]
Title: Portal Hypertension
Category: Diseases and Conditions
Created: 1/31/2005 12:00:00 AM
Last Editorial Review: 9/6/2016 12:00:00 AM
Published Studies Related to Tenoretic (Atenolol / Chlorthalidone)
[A comparative study of atenolol (Tenormin) and the combined preparation atenolol/chlorthalidone (Tenoretic Mite) in essential hypertension. A randomized double-blind study from general practice] [1990.04.09]
Two hundred and ninety-two hypertensive patients from general practice who had previously been treated with a diuretic with insufficient effect participated in a randomised trial for a period of three months. A total of 115 patients completed treatment with 50 mg atenolol (Tanormin) and 121 were treated with the combined preparation consisting of 50 mg atenolol and 12.5 mg chlothalidone (Tenoretic Mite) while 56 patients defected from the trial.
Assessment of a fixed-dosage combination of atenolol and chlorthalidone (Tenoretic) in hypertensive Nigerians. [1990.03]
The antihypertensive effect of a fixed dosage combination of the cardioselective beta-adrenoceptor blocker, atenolol, and the oral thiazide-like diuretic, chlorthalidone (Tenoretic) was studied in 24 hypertensive Nigerians in a double-blind, cross-over comparison with three other treatments... The drugs were well tolerated.
Atenolol and chlorthalidone therapy for hypertension: a double-blind comparison. [1988.11]
In a randomized, double-blind, parallel-group study of 31 patients with mild to moderate hypertension, we compared a placebo regimen with a regimen of atenolol and chlorthalidone (Tenoretic). The study, which lasted seven weeks, began with a single-blind two-week placebo lead-in period, followed by a four-week double-blind treatment phase, and concluded with a one-week single-blind placebo washout period.
[Photoallergy to Neotri and cross reaction to tenoretic--detection by systemic photoprovocation] [1988.01]
A patient is presented who suffered for 3 years from increasing photosensitivity with chronic eczematous lesions in sun-exposed areas...
Clinical Trials Related to Tenoretic (Atenolol / Chlorthalidone)
EBMtrialcentral- Comparing Initial Diuretic Therapies Using a Collaborative Network [Not yet recruiting]
- Clinical equipoise exists with respect to the important question, "What is the best
initial diuretic for the treatment of Hypertension"? A pragmatic comparative
effectiveness research (CER) study comparing Chlorthalidone to Hydrochlorthiazide could
help inform decision making for this common problem.
- The investigators aim to harness both the power of bioinformatics (using web-based
data-capture and electronic health records) and of online media (through collaboration)
in order to facilitate such a CER in "usual-care" settings. This process may also
provide a foundation for testing a wealth of important clinical questions which
commonly arise in the delivery of contemporary healthcare and would otherwise be left
- To this end the investigators are developing a website, EBMtrialcentral, where eligible
physicians can go online and join their collaborative network. Physicians can then
enroll eligible patients in this study. These will include under-served urban patients.
Clinical information will be entered online (using a secure database housed at Johns
Hopkins), patient consent will be obtained electronically and treatment recommendations
will be randomly allocated to either 25mg daily of oral HCTZ or 12. 5mg daily of oral
Chlorthalidone. The investigators aim to increase to 50mg HCTZ and 25mg Chlorthalidone
over 8 weeks and compare their effects on BP measured with a 24 hour monitor.
- The investigators' primary hypothesis is that non-blinded, random, parallel allocation
of 12. 5mg daily Chlorthalidone (titrated to 25mg at 4 weeks) will demonstrate a
clinically meaningful ≥5mmHg improvement in BP control (as measured by change in BP
from baseline using 24hr ABPM) compared to 25mg daily HCTZ (titrated to 50mg at 4
weeks) in newly hypertensive patients followed in a usual-care clinic setting over 8
weeks. They will also analyze differences in side-effects or safety (serum
electrolytes) between these two medications.